Lilly's Acquisition of POINT Biopharma Boosts Oncology Capabilities with Next-Gen Radioligand Therapies

Eli Lilly and Company has announced its acquisition of POINT Biopharma, a radiopharmaceutical company focused on developing radioligand therapies for cancer treatment. Radioligand therapy involves delivering radiation directly to cancer cells, minimizing damage to healthy tissue. POINT's lead programs include a radioligand therapy for metastatic castration-resistant prostate cancer and another for gastroenteropancreatic neuroendocrine tumors. The acquisition will allow Lilly to expand its oncology capabilities and develop a pipeline of radioligand treatments for hard-to-treat cancers. The deal is expected to close by the end of 2023.